Drug Development

Agouron Reports Anticancer Collaboration with U.K. Organizations

Published in Gene Therapy Weekly, October 20th, 1997

Agouron Pharmaceuticals, Inc., La Jolla, California, announced an agreement with the University of Newcastle Upon Tyne (Newcastle) and Cancer Research Campaign Technology (CRCT) in the United Kingdom under which the organizations will collaborate to discover and develop a new class of anti-cancer drugs.

Under the agreement, CRCT has licensed Agouron patented prototype inhibitors of the enzyme poly ADP-ribose polymerase (PARP) discovered by the Anti-cancer Drug Discovery Initiative (ADDI) at Newcastle. PARP has been shown to play a key role in the ability of certain human cancers to evade currently available anti-tumor drugs.

Agouron will support...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry